BIOMAT Database Logo BIOMAT Database Logo

Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failure. 1998

V Miller, and A Phillips, and C Rottmann, and S Staszewski, and R Pauwels, and K Hertogs, and M P de Béthune, and S D Kemp, and S Bloor, and P R Harrigan, and B A Larder
Zentrum der Inneren Medizin, Klinikum der J.W. Goethe-Universität, Frankfurt, Germany. miller@em.uni-frankfurt.de

Human immunodeficiency virus type 1 (HIV-1) strains dually resistant to zidovudine and lamivudine (3TC) may arise during zidovudine-3TC combination therapy. The objective of this cross-sectional study (n = 43 patients) was to test the association between therapy response (clinical and immunologic) to zidovudine-3TC and the level of phenotypic zidovudine resistance and zidovudine resistance-associated genotype of 3TC-resistant isolates. Other variables included were baseline CD4+ cell count, baseline Centers for Disease Control and Prevention (CDC) classification, virus load, and time receiving zidovudine. Phenotypic resistance was assessed using a recombinant virus assay. Genotypic analysis was based on population sequencing of plasma HIV-1. In a univariate analysis using a logistic regression model, it was found that therapy response was significantly associated with phenotypic and genotypic zidovudine resistance, baseline CD4+ cell count, and virus load. After adjustment for all variables, phenotypic resistance to zidovudine remained the only significantly associated factor, independent of baseline CD4+ cell count, baseline CDC classification, and virus load.

UI MeSH Term Description Entries
D003430 Cross-Sectional Studies Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time. Disease Frequency Surveys,Prevalence Studies,Analysis, Cross-Sectional,Cross Sectional Analysis,Cross-Sectional Survey,Surveys, Disease Frequency,Analyses, Cross Sectional,Analyses, Cross-Sectional,Analysis, Cross Sectional,Cross Sectional Analyses,Cross Sectional Studies,Cross Sectional Survey,Cross-Sectional Analyses,Cross-Sectional Analysis,Cross-Sectional Study,Cross-Sectional Surveys,Disease Frequency Survey,Prevalence Study,Studies, Cross-Sectional,Studies, Prevalence,Study, Cross-Sectional,Study, Prevalence,Survey, Cross-Sectional,Survey, Disease Frequency,Surveys, Cross-Sectional
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D017211 Treatment Failure A measure of the quality of health care by assessment of unsuccessful results of management and procedures used in combating disease, in individual cases or series. Failure, Treatment,Failures, Treatment,Treatment Failures

Related Publications

V Miller, and A Phillips, and C Rottmann, and S Staszewski, and R Pauwels, and K Hertogs, and M P de Béthune, and S D Kemp, and S Bloor, and P R Harrigan, and B A Larder
Emergence of dual resistance to zidovudine and lamivudine in HIV-1-infected patients treated with zidovudine plus lamivudine as initial therapy.
January 2000, Journal of acquired immune deficiency syndromes (1999),
V Miller, and A Phillips, and C Rottmann, and S Staszewski, and R Pauwels, and K Hertogs, and M P de Béthune, and S D Kemp, and S Bloor, and P R Harrigan, and B A Larder
Zidovudine resensitization and dual HIV-1 resistance to zidovudine and lamivudine in the delta lamivudine roll-over study.
January 1999, Antiviral therapy,
V Miller, and A Phillips, and C Rottmann, and S Staszewski, and R Pauwels, and K Hertogs, and M P de Béthune, and S D Kemp, and S Bloor, and P R Harrigan, and B A Larder
Profound and unanticipated anemia with lamivudine-zidovudine combination therapy in zidovudine-experienced patients with HIV infection.
March 1998, AIDS (London, England),
V Miller, and A Phillips, and C Rottmann, and S Staszewski, and R Pauwels, and K Hertogs, and M P de Béthune, and S D Kemp, and S Bloor, and P R Harrigan, and B A Larder
Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
July 1996, JAMA,
V Miller, and A Phillips, and C Rottmann, and S Staszewski, and R Pauwels, and K Hertogs, and M P de Béthune, and S D Kemp, and S Bloor, and P R Harrigan, and B A Larder
Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy.
January 2008, AIDS (London, England),
V Miller, and A Phillips, and C Rottmann, and S Staszewski, and R Pauwels, and K Hertogs, and M P de Béthune, and S D Kemp, and S Bloor, and P R Harrigan, and B A Larder
[Lamivudine-zidovudine combination treatment].
October 1996, Deutsche medizinische Wochenschrift (1946),
V Miller, and A Phillips, and C Rottmann, and S Staszewski, and R Pauwels, and K Hertogs, and M P de Béthune, and S D Kemp, and S Bloor, and P R Harrigan, and B A Larder
Precipitous declines in hemoglobin levels associated with combination zidovudine and lamivudine therapy.
October 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
V Miller, and A Phillips, and C Rottmann, and S Staszewski, and R Pauwels, and K Hertogs, and M P de Béthune, and S D Kemp, and S Bloor, and P R Harrigan, and B A Larder
Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
July 1996, JAMA,
V Miller, and A Phillips, and C Rottmann, and S Staszewski, and R Pauwels, and K Hertogs, and M P de Béthune, and S D Kemp, and S Bloor, and P R Harrigan, and B A Larder
Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine or stavudine, each in combination with lamivudine and indinavir.
December 2002, Journal of acquired immune deficiency syndromes (1999),
V Miller, and A Phillips, and C Rottmann, and S Staszewski, and R Pauwels, and K Hertogs, and M P de Béthune, and S D Kemp, and S Bloor, and P R Harrigan, and B A Larder
Switching to lopinavir/ritonavir with or without abacavir/lamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudine.
June 2013, The Journal of antimicrobial chemotherapy,
Copied contents to your clipboard!